- Home
- UEIC vs RLMD Comparison
UEIC vs RLMD Comparison
Compare UEIC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEIC
- RLMD
- Stock Information
- Founded
- UEIC 1986
- RLMD 2004
- Country
- UEIC United States
- RLMD United States
- Employees
- UEIC N/A
- RLMD N/A
- Industry
- UEIC Consumer Electronics/Appliances
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- UEIC Consumer Staples
- RLMD Health Care
- Exchange
- UEIC Nasdaq
- RLMD Nasdaq
- Market Cap
- UEIC 103.5M
- RLMD 110.6M
- IPO Year
- UEIC 1993
- RLMD N/A
- Fundamental
- Price
- UEIC $10.95
- RLMD $3.01
- Analyst Decision
- UEIC Strong Buy
- RLMD Hold
- Analyst Count
- UEIC 2
- RLMD 2
- Target Price
- UEIC $14.50
- RLMD $7.50
- AVG Volume (30 Days)
- UEIC 63.0K
- RLMD 117.3K
- Earning Date
- UEIC 11-07-2024
- RLMD 11-07-2024
- Dividend Yield
- UEIC N/A
- RLMD N/A
- EPS Growth
- UEIC N/A
- RLMD N/A
- EPS
- UEIC N/A
- RLMD N/A
- Revenue
- UEIC $382,019,000.00
- RLMD N/A
- Revenue This Year
- UEIC N/A
- RLMD N/A
- Revenue Next Year
- UEIC $6.86
- RLMD N/A
- P/E Ratio
- UEIC N/A
- RLMD N/A
- Revenue Growth
- UEIC N/A
- RLMD N/A
- 52 Week Low
- UEIC $7.17
- RLMD $1.88
- 52 Week High
- UEIC $14.20
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- UEIC 70.98
- RLMD 31.18
- Support Level
- UEIC $10.44
- RLMD $3.06
- Resistance Level
- UEIC $11.71
- RLMD $3.43
- Average True Range (ATR)
- UEIC 0.48
- RLMD 0.20
- MACD
- UEIC 0.28
- RLMD -0.05
- Stochastic Oscillator
- UEIC 79.23
- RLMD 6.61
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.